SCHEMBL4361247

SCHEMBL4361247

Cc1ccc(C(=O)c2cnc(N(C3CCNCC3)S(C)(=O)=O)nc2N)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK1 P06493 8/20 0.42
CDK4 P11802 7/20 0.42
CCND1 P24385 7/20 0.42
CDK2 P24941 7/20 0.42
MEN1 O00255 1/20 0.38
CYP2D6 P10635 1/20 0.38
KMT2A Q03164 1/20 0.38
PLAT P00750 1/20 0.36
SYK P43405 2/20 0.33
KCNH2 Q12809 2/20 0.33
MAPK3 P27361 1/20 0.33
MAPK1 P28482 1/20 0.33
AURKB Q96GD4 1/20 0.33
ADRA2A P08913 1/20 0.32
HRH1 P35367 1/20 0.32
HTR2B P41595 1/20 0.32
MCHR1 Q99705 1/20 0.32
MAPT P10636 3/20 0.32
SMN1; SMN2 Q16637 3/20 0.32
ALDH1A1 P00352 3/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4350748 0.91 CDK1 (0.39) CDK1CDK4CCND1CDK2ADRA2A
SCHEMBL4352658 0.91 CDK1 (0.41) CDK1CDK4CCND1CDK2KCNH2
SCHEMBL3519635 0.91 CDK2 (0.45) CDK1CDK4CCND1CDK2KCNH2
SCHEMBL4346544 0.89 CDK1 (0.44) CDK1CDK4CCND1CDK2MEN1
SCHEMBL4350391 0.85 CDK1 (0.51) CDK1CDK4CCND1CDK2MAPT
SCHEMBL4350415 0.83 BTK (0.42) CDK1CDK4CCND1CDK2SYK
SCHEMBL4360994 0.82 CDK1 (0.45) CDK1CDK4CCND1CDK2PLAT
SCHEMBL4352515 0.82 CDK1 (0.65) CDK1CDK4CCND1CDK2
SCHEMBL4350208 0.82 CDK1 (0.47) CDK1CDK4CCND1CDK2KCNH2
SCHEMBL3522557 0.82 CDK2 (0.54) CDK1CDK4CCND1CDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7157455-B2 4-Aminopyrimidine-5-one derivatives HOFFMANN-LA ROCHE INC. (US) 2007-01-02 US claimed
EP-1628619-A2 4-AMINOPYRIMIDINE-5-ONE F.HOFFMANN-LA ROCHE AG (CH) 2006-03-01 EP claimed
US-20040162303-A1 4-aminopyrimidine-5-one derivatives BARTKOVITZ DAVID JOSEPH (US) 2004-08-19 US claimed
WO-2004069139-A2 4-AMINOPYRIMIDIN-5-YL-METHANONE DERIVATIVES FOR INHIBITION OF CDK4 ACTIVITY F.HOFFMANN-LA ROCHE AG (CH) 2004-08-19 WO claimed
US-7615634-B2 4-aminopyrimidine-5-one derivatives HOFFMANN-LA ROCHE INC. (US) 2009-11-10 US disclosed
US-7157455-B2 4-Aminopyrimidine-5-one derivatives HOFFMANN-LA ROCHE INC. (US) 2007-01-02 US disclosed
US-20060229330-A1 4-aminopyrimidine-5-one derivatives BARTKOVITZ DAVID J 2006-10-12 US disclosed
EP-1463742-A4 NOVEL PYRAZOLO-AND PYRROLO-PYRIMIDINES AND USES THEREOF ARIAD PHARMA INC (US) 2006-05-10 EP disclosed
EP-1628619-A2 4-AMINOPYRIMIDINE-5-ONE F.HOFFMANN-LA ROCHE AG (CH) 2006-03-01 EP disclosed
EP-1463742-A2 NOVEL PYRAZOLO-AND PYRROLO-PYRIMIDINES AND USES THEREOF ARIAD PHARMACEUTICALS, INC. (US) 2004-10-06 EP disclosed
US-20040162303-A1 4-aminopyrimidine-5-one derivatives BARTKOVITZ DAVID JOSEPH (US) 2004-08-19 US disclosed
WO-2004069139-A2 4-AMINOPYRIMIDIN-5-YL-METHANONE DERIVATIVES FOR INHIBITION OF CDK4 ACTIVITY F.HOFFMANN-LA ROCHE AG (CH) 2004-08-19 WO disclosed
WO-2003000187-A2 NOVEL PYRAZOLO-AND PYRROLO-PYRIMIDINES AND USES THEREOF ARIAD PHARMACEUTICALS, INC. (US) 2003-01-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040162303-A1 4-aminopyrimidine-5-one derivatives CDK4, CDKL4, CDK6 CDK1 6/4885CDK4 1/4885CCND1 32/4885
US-20060229330-A1 4-aminopyrimidine-5-one derivatives CDK4, CDKL4, CDK2 CDK1 6/4885CDK4 1/4885CCND1 31/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.